Blogs
If an analyte is amenable to analysis, it’s difficult to ignore the benefits that LC-MS/MS can provide. There are numerous challenges associated with using LC-MS/MS for the bioanalysis of oligonucleotides that have slowed its utilization for these assays. These include: However, the increased adoption of LC-MS/MS for oligonucleotides…
Posters & Papers
KCAS Bio collaborated with Phenomenex to demonstrate how magnetic bead-enabled hybrid LC-MS workflows are advancing modern bioanalysis for increasingly complex biotherapeutics. The case study explores how magnetic bead-based affinity capture enhances selectivity, sensitivity, and multiplexing, enabling more reliable quantitation of modalities such as monoclonal antibodies, ADCs,…
Posters & Papers
Discover in this poster presented by Rathna Veeramachaneni, Ph.D. at the American Society for Mass Spectrometry (ASMS) Conference in 2026 about the various developmental parameters to consider for fit-for-purpose validation of a novel multiplexed hybrid LC–MS/MS assay for the simultaneous quantitation of two abundant biomarkers in human heart tissue.
Posters & Papers
Discover in this poster presented by Andrew Bergdorf at the American Society for Mass Spectrometry (ASMS) Conference in 2026 about how we developed a streamlined, high-throughput proteomics workflow for human heart tissue that reduces sample preparation time while maintaining robust and reproducible biomarker detection. Key optimizations in…
Posters & Papers
Discover in this poster presented by Amrit Chakravarty, Ph.D. at the AAPS National Biotechnology Conference in 2026 about a high-sensitivity bioanalytical workflow combining single-use tip-based online cleanup on the Evosep Eno platform with a microflow LC-MS/MS setup on a SCIEX Triple Quad 7500+. The approach enables robust…
Videos
Full laboratory tour of the KCAS Bio location in Kansas City, KS USA. Interested in speaking with one of our experts? Fill out the form below to connect with a KCAS Bio scientist.
Videos
The SCIEX 7500+ system offers ultrasensitive quantitation, rigorously tested on challenging matrices. It ensures reliable detection of low-level compounds in complex samples while minimizing downtime. Featuring: Rathna Veeramachaneni, Ph.D. Interested in speaking with one of our experts? Fill out the form below to connect with…
Blogs
Accurately quantifying cisplatin in human plasma by LC-MS/MS can be challenging due to matrix effects caused by endogenous plasma components, particularly in hemolyzed samples. At WRIB 2025, scientists from KCAS Bio and Lilly presented a novel bioanalytical approach designed to…
Blogs
Oligonucleotide therapeutics continue to reshape drug development by targeting disease pathways at the genetic level. Antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and antibody-RNA conjugates (ARCs) are expanding the range of treatable diseases, particularly for targets that were previously considered inaccessible to conventional therapeutics. As these modalities evolve,…
Blogs
In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in…
Posters & Papers
Discover in this poster presented by Taylor Dufield at WRIB 2026 about a fit-for-purpose multiplex LC–MS/MS workflow combining online and offline anti-peptide immunoprecipitation that enables sensitive, selective quantitation of protein biomarkers and binding partners from a single digested tissue sample across multiple species using a validated ICH M10-aligned approach.
Posters & Papers
Discover in this poster presented by Ryan Darling at WRIB 2026 on how a validated hybrid immunoaffinity LC–MS/MS method using a surrogate peptide and 2D chromatography enables selective, sub-ng/mL quantitation of a KLK1 analog in human plasma, overcoming LBA limitations caused by near-identical endogenous KLK1. If you have…